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1. Introduction
  The increasing burden of malaria has contributed 
significantly to poverty, decreased productivity and slow 
economic growth in malaria endemic regions[1]. In 2010 
alone, an estimated 655 000 cases of malaria-associated 
deaths were recorded, especially in very young African 
children[2,3]. This trend is attributed mainly to growing 
resistance of the Plasmodium parasite to drugs like 
chloroquine and sulphadoxine/pyrimethamine that were 
previously effective[4] but are now widely ineffective. 
Parasite resistance to commonly used antimalarials such 
as chloroquine and sulphadoxine/pyrimethamine has also 
been found to confer cross resistance to other antimalarial 
drugs[5]. Excessive and dysregulated inflammatory 
responses in patients infected with Plasmodium falciparum 
(P. falciparum) has also been linked with the development 
of severe forms of malaria exemplified by cerebral malaria, 
which accounts for 15%-40% mortality in such patients[6]. 
Prompt and effective treatment remains the primary option 
for the management of malaria in tropical areas where the 
disease is endemic with high transmission rates.
  The World Health Organization currently advocates 
artemisinin derivatives and their combinations for 
the treatment of malaria[7]. However, poverty in many 
developing countries,  especially in Africa, puts 
artemisinin-based therapies out of the reach of many. This 
inaccessibility is still largely responsible for the increasing 
incidence of morbidity and mortality associated with 
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malaria infection. Recent reports[8,9] have also shown that P. 
falciparum is becoming resistant to artemisinin. Therefore, 
there is the need for continuous search for new antimalarial 
drugs and the use of plants as a promising strategy is on the
increase[10,11]. Novel compounds with potent antiplasmodial 
activity isolated from natural products offer an attractive 
source of promising antimalarial agents. This is especially 
true for plants with long history of use in ethno medical 
practice, as some of the antimalarials used today were 
derived from such plants. The most significant examples 
are quinine, isolated from barks of Cinchona succirubra 
and Cinchona calisaya[12] and artemisinin, obtained from 
Artemisia annua[13]. Phyllanthus niruri (Euphorbiaceae) 
(P. niruri) is an annual herbaceous plant indigenous to 
rain forests, tropical and sub tropical areas of the world. 
Preparations of its dried aerial parts are used to stimulate 
appetite and to treat malaria in Thailand[14] and the 
West Indies[15]. It is also a popular antipyretic remedy 
in South America[16]. An aqueous extract of the aerial 
parts of the plant is also used to break and expel kidney 
stones in India, Brazil and other Amazonian regions. 
Harish and Shivanandappa reported[17] that the alcoholic 
and aqueous extracts of the leaves and fruit exhibit 
antioxidant, free radical scavenging and hepatoprotective 
effects. Antiplasmodial activity of aqueous, methanol and 
chloroform extracts of the plant has also been demonstrated 
by Mustofa et al[18]. Phytoconstituents present in the P. 
niruri responsible for its pharmacological properties include 
lignans, alkaloids, flavonoids, benzenoids, coumarins, 
tannins, diterpenes, triterpenes, sterols, phytallates and 
lipids[19]. To date, no information was found in literature 
regarding the components of the organic extracts responsible 
for its antiplasmodial activity. The significant medicinal 
activity of P. niruri[17-19] also underscores the need to assure 
quality and consistency of its pharmacological effects by 
identifying phytochemical markers and fingerprints, a basic 
requirement for validating and standardizing medicinal 
plants[20]. 
  Our study is therefore aimed at investigating the 
antiplasmodial activity of P. niruri methanol extract and 
fractions, to identify the most active fraction using mouse 
models of infection.   
2. Materials and methods
2.1. Plant material
  Fresh aerial parts of P. niruri were collected in June 2008 
from an uncultivated farmland in Orba, Enugu State, Nigeria. 
The plant material was identified and authenticated by Mr 
A. Ozioko of the International Centre for Ethno medicines 
and Drug Development (InterCEDD) Nsukka, Enugu state. 
A voucher specimen was prepared and deposited in NIPRD 
herbarium (NIPRD/H/6565). The roots of the plant were cut 
off and the aerial parts dried at room temperature for two 
weeks then pulverized to coarse powder using an electric 
hammer mill.
2.2. Extraction and fractionation
  The powdered plant material (900 g) was extracted with 5.85 L
methanol (98% v/v) for 48 h with occasional mechanical 
shaking (4 h/day). At the end of 48 h, the mixture was 
filtered using ashless filter paper (Whatman, USA), the 
residue reconstituted in 4 L of methanol (98% v/v) and the 
extraction process repeated. The filtrates were pooled 
together and concentrated under reduced pressure using 
a rotary evaporator to afford 98 g of the crude methanol 
extract (ME). A 33 g quantity of ME was portioned between 
water and chloroform (4 伊 600 mL) using a separatory funnel. 
The combined lower chloroform layer was concentrated to 
dryness under vacuum by rotary evaporation at 40 曟 and 
the slurry obtained was designated F1 (9.09% w/w). The 
upper aqueous layer was concentrated on a water bath and 
extracted with ethanol (96% v/v). The ethanol extract was 
concentrated under vacuum and evaporated to dryness to 
give a brown, sticky fraction, F2 (18.18%). The residue left 
after extraction with ethanol was evaporated to dryness on 
a water bath to give a brown powder, F3 (54.55%). The crude 
extract and its fractions were stored in a refrigerator until 
required.
2.3. Phytochemical screening
  Phytochemical screening of the crude extract and fractions 
was carried out in accordance with standard test procedures 
described by Evans[21].   
2.4. Animals 
  Swiss albino mice of either sex weighing 18-25 g were 
acclimatized for two weeks to laboratory conditions in 
the animal facility centre of the National Institute for 
Pharmaceutical Research and Development (NIPRD), Abuja. 
The mice were housed in plastic cages in a ventilated room 
at a temperature of (20 依 5) 曟, fed with standard rodent chow 
and allowed free access to potable water.  All experiments 
were carried out in accordance with NIH Guide for the Care 
and Use of Laboratory Animals; NIH publication (No 82-23) 
revised, 1985[22] and NIPRD’s standard operating procedures.
2.5. Rodent parasite 
  Chloroquine-sensitive rodent parasite (NK 65 strain) was 
sourced from the National Institute for Medical Research 
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(NIMR), Lagos, Nigeria. The parasite was maintained by 
continuous reinfection (intraperitoneal) of healthy mice.
2.6. Parasite inoculation
  One week after parasite inoculation, a leishman-stained 
thin blood film was prepared from tail vein blood of a donor 
mouse on the surface of a glass slide for the assessment of 
parasitaemia and its red blood cell count determined with a 
Neubauer hemocytometer. Using the parasitaemia and red 
blood cell count of the donor mouse, the withdrawn blood 
sample was diluted with normal saline such that 0.2 mL 
contained approximately 105 parasitized red blood cells. 
Each experimental mouse was inoculated intraperitoneally 
with 0.2 mL of the diluted infected blood.
2.7. Preliminary antiplasmodial assessment of extract and 
fractions in early infection (4-day test) 
  The method described by Kalra et al[23] was adopted. 
Briefly, sixty mice were randomized into groups of five mice 
each, such that mean weight within each group was kept 
close. On day 0, within 4 h after inoculation of mice with 
the parasite, treatment of all the groups was initiated orally. 
Groups 1 and 2 served as controls and received distilled 
water and chloroquine (5 mL and 5 mg/kg b.w., respectively), 
while groups 3, 4 and 5 received 100, 200 and 400 mg ME/
kg b.w., respectively. Graded doses (25-100 mg/kg b.w.) of 
the fractions were administered to groups 6-14. Treatment 
was carried out at the same time each day on days 1, 2 and 
3. On day 4, thin films of tail vein blood were prepared and 
stained with Leishman’s stain. The films were examined 
microscopically and parasitaemia was expressed as the 
mean number of parasitized erythrocytes counted in 10 
fields of approximately 250 erythrocytes per field.
  Percentage suppression of parasitaemia was calculated 
using the following equation[24]:
  Mean parasitaemia control - mean parasitaemia treated 伊 
100 / mean parasitaemia control 
  Based on the outcome of this preliminary test, the 
chloroform fraction was selected for further antiplasmodial 
screening.
2.8. Effect of ME and F1 on established infection
  The schizonticidal activity of the crude extract and in 
established infection was evaluated using the method of 
Ryley and Peters described by Okokon and Nwafor[25]. 
Forty mice were injected intraperitoneally with dilute 
infected blood as described above. On day 3, thin blood 
films of the mice were prepared to determine pre-treatment 
parasitaemia. The mice were randomized into eight groups 
of five mice each such that mean parasitaemia of the groups 
were close. Treatment was then carried out as follows: Group 
1 and 2 served as controls and received distilled water and 
chloroquine (5 mg/kg b.w.) respectively, while groups 6, 7 
and 8 were treated with 100, 200 and 400 mg ME/kg b.w. 
respectively, groups 9-11 were given 25-100 mg F1/kg b.w. 
Treatment was continued once daily on days 4 to 6. On day 
7, blood films were made and the level of parasitaemia 
assessed. The mice were subsequently monitored for 
mortality and mean survival time of each group was 
recorded.   
  
2.9. Assessment of prophylactic antiplasmodial activity of ME 
and F1 
  The prophylactic effect of ME and F1 against infection was 
assessed using the method of Peters, described by Chandel 
and Bagai[26]. Forty mice were randomized into eight groups 
(n=5) and treated once daily for three consecutive days. 
Control groups 1 and 2 received distilled water (5 mL/kg b.w) 
and pyrimethamine (1.2 mg/kg b.w.) respectively, while the 
remaining groups were treated with ME (100, 200 and 400 
mg/kg b.w.) and F1 (25, 50 and 100 mg/kg b.w.). On the fourth 
day, the mice were inoculated with Plasmodium berghei 
berghei. After 72 h, a thin blood film of each mouse was 
made and parasitaemia was assessed.
2.10. Effect of F1 on erythrocyte viability
  The effects of F1 on viability of parasitized and non-
parasitized red blood cells in vitro were studied using 
the trypan blue exclusion technique[27]. In brief, blood 
was withdrawn from the retro orbital plexuses of infected 
and uninfected mice into EDTA-containing plastic tubes, 
centrifuged and the packed cells washed thrice in phosphate 
buffered saline (PBS). A 100 毺L volume of a 10% cell 
suspension was prepared in PBS containing 5% dextrose 
was mixed with 100 毺L of serial dilutions of F1 prepared in 
dimethylsulfoxide and PBS (1:9). The mixture was incubated 
at 37 曟 for 45 min then mixed with an equal volume of 4% 
trypan blue and allowed to stand for 3 min. The total number 
of cells was counted and the viable cells counted separately, 
using a hemocytometer. The test was done in triplicates for 
each concentration used.  
2.11. HPLC fingerprinting of the crude extract and 
chloroform fraction
  Chromatographic fingerprinting of ME and F1 by HPLC 
was carried out using a Shimadzu LC-20AB Prominence 
model composed of a programmable auto sampler (SIL-20AC 
prominence), a Shimadzu SPD-M20A Prominence UV-diode 
array detector and a binary pump equipped with a degasser 
(Shimadzu, Kyoto, Japan). The analytical column was a 
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reversed-phased column Shim-Pack VP-ODS (150 mm 伊 
4.6 mm id., 4.6 毺m particle size; Shimadzu, Kyoto, Japan). 
The column temperature was 28 曟. The mobile phase which 
gave maximum separation consisted of 0.2% v/v formic 
acid solution and acetonitrile (80:20) by isocratic elution. 
Flow rate was 0.6 mL/min. and volume injected was 10 毺L.
The samples were detected at 254 nm using photodiode 
array detector. Data analysis was performed with Shimadzu
Lab Solutions LCsolution software (version 1.23 SP1).
2.12. Data analysis
  Results were expressed as mean 依 SEM. Statistical analyses 
was carried out by one-way ANOVA (GraphPad Prism 3.0), 
data was further subjected to dunnett’s post hoc test and 
differences between treated groups and control accepted as 
significant at P<0.01 and P<0.05.
3. Results 
  Figure 1A shows the fingerprint of ME with five 
characteristic peaks of varying relative compositions while 
a total of fourteen peaks were seen in the fingerprint profile 
of F1 (Figure 1B). Results in Table 1 show the constituents 
of P. niruri methanol extract and its fractions.  Phenols 
and alkaloids were detected in the crude extract, aqueous, 
ethanol and chloroform fractions, while terpenes, sterols 
and anthraquinones were present in the extract, its ethanol 
and chloroform fractions. Saponins, tannins and flavonoids 
detected in ME also presented in the aqueous and ethanol 
fractions. All the fractions except the chloroform fraction 
were devoid of volatile oils. 
Table 1
Phytochemical composition of P. niruri methanol extract and its 
fractions.
ME F1 F2 F3
Carbohydrates + ND ND +
Terpenes + + + ND
Sterols + + + ND
Saponins + ND + +
Cardiac glycosides ND ND ND ND
Tannins + ND + +
Anthraquinones + + + ND
Balsams ND ND ND ND
Resins ND ND ND ND
Alkaloids + + + +
Phlobatannin ND ND ND ND
Flavonoids + ND + +
Phenols    + + + +
Volatile oil                                               + + ND ND
+: Detected; ND: Not detected, PNME= P. niruri methanol extract, 
F1= chloroform fraction, F2= ethanol fraction, F3= aqueous fraction.
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Figure 1. HPLC chromatogram of chloroform fraction of P. niruri 
methanol extract (A) & P. niruri methanol extract (B).
  Results in Figure 2 show a dose-dependent suppression of 
parasitaemia by ME and is chloroform, ethanol and aqueous 
fractions in early infection. At 100-400 mg/kg b.w., ME 
suppressed parasitaemia by 37.65%-50.53%. The effect of 
the extract was significant (P<0.01) at 400 mg/kg b.w. The 
aqueous fraction, F3, was the least effective of the three 
fractions, suppressing parasitaemia by 21.18% - 51.18%, eliciting 
significant (P<0.01) activity only at a dose of 100 mg/kg b.w.
The ethanol fraction (F2) had intermediate activity, 
producing significant (P<0.01) suppression of the parasite 
at 50 (64.71%) and 100 (67.06%) mg/kg b.w. The chloroform 
fraction possessed remarkable plasmodial suppressive 
activity. It significantly (P<0.01) reduced parasitaemia at 25 
(49.41%), 50 (72.94%) and 100 (85.29%) mg/kg b.w. Its effect 
at 100 mg/kg b.w was comparable to the effect produced by 
chloroquine (89.41%). 
  As shown in Table 2, ME significantly (P<0.01) reduced 
parasitaemia in established infection at 200 (34.11%) and 400 
(62.96%) mg/kg doses. Mean survival time was observed to 
increase in PNME-treated mice although this increase was 
insignificant (P>0.05), whereas mean survival time increased 
significantly (P<0.05) in the chloroquine-treated group. 
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Comparatively, F1 dose-dependently and significantly 
(P<0.01) reduced parasitaemia by 44.36%-90.48%. In 
particular, a dose of 100 mg/kg b.w. significantly (P<0.01) 
increased mean survival time and favourably compared with 
chloroquine in this respect, unlike the crude extract. 
  In Figure 3, it was shown that ME and F1 also exhibited 
good prophylactic activity in repository infection. ME 
significantly (P<0.01) reduced parasitaemia at all the doses 
used, causing 67.5%-92.5% decrease in parasitaemia. It is 
noteworthy that the effect of the extract at 200 mg/kg b.w. 
was comparable to the effect of the standard reference drug, 
pyrimethamine. A dose of 400 mg/kg b.w. ME was more 
effective than pyrimethamine (1.2 mg /kg b.w.), reducing 
parasitaemia by 92.5% and 85.0% respectively. Significant 
prophylactic activity of F1 was also evident at 50 and
100 mg/kg b.w., yielding 55% and 60% (P<0.01) reduction of 
parasitaemia respectively. 
  The anti-hemolytic test carried out showed overall non-
cytotoxicity of F1 to non-infected erythrocytes (Figure 
4). However, cell membrane integrity of parasitized 
erythrocytes incubated with 125-500 mg/mL F1 improved 
in a concentration dependent manner, as concentrations of 
250 and 500 mg/mL increased cell viability by 22.61% and 
30.26%, respectively. 
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Figure 2. Antiplasmodial activity of P. niruri extract and its solvent 
fractions in early infection.
**significantly different from control at P<0.01 (n=5), values in 
parenthesis represent percentage suppression relative to control.
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4. Discussion 
  The herbal raw material is prone to a lot of variation due to 
several factors, the important ones being the identity of the 
plants and seasonal variation (which has a bearing on the 
time of collection), the ecotypic, genotypic and chemotypic 
Table 2
Effect of P. niruri methanol extract and its chloroform fraction on established infection in mice. 
Treatment Dose Parasitaemia Day 3 Day 6 Mean survival time (days) % suppression
Distilled water - 4.31依0.62 6.83依0.54 16.60依0.40 -
PNME 100 4.27依0.36 5.75依0.54 17.00依0.68 15.81
200 5.40依0.51   4.50依0.56** 17.60依1.91 34.11
400 3.10依0.84   2.53依0.45** 19.40依1.83 62.96
F1   25 5.40依0.67   3.80依0.76** 18.60依0.68 44.36
  50 4.20依0.83   0.75依0.25** 18.20依0.74 89.01
100 4.25依0.51   0.65依0.26**   22.80依1.59** 90.48
Chloroquine     5 4.55依0.46   0.24依0.09** >30** 96.48
PNME = Phyllanthus niruri methanol extract, F1= Chloroform fraction, **significantly different from control at P <0.01 (n=5).
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variations, drying and storage conditions and the presence 
of xenobiotics. The National Center for Complementary and 
Alternative Medicine and the WHO stress the importance of 
the qualitative and quantitative methods for characterizing 
the samples, quantification of the biomarkers and/ or 
chemical markers and the fingerprint profiles. It is a 
challenging task to develop suitable standards for herbal 
drugs. The advancements in modern methods of analysis 
and the development of their application have made it 
possible to solve many of these problems. Extremely 
valuable are techniques like high-performance thin-layer 
chromatography (HPTLC), gas chromatography (GC), mass 
spectrometry (MS) LC-MS, GC-MS and HPLC which has been 
applied in this study. The method validation of fingerprint 
analysis was performed based on the relative retention time 
and the relative peak area. 
  Based on these retention times, all the peaks seen in ME 
except peak 48 were common to F1, although their relative 
compositions differed. These chromatograms would serve 
as useful fingerprints, for the identification of P. niruri 
methanol extract and its chloroform fraction.
  The secondary metabolites detected in the methanol extract 
used in our study show consistency with previous reports 
on phytochemical composition of P. niruri[19]. In the present 
study, the methanol extract of this extract exhibited potent 
activity. Our findings are supported by Mustofa et al[18], who 
reported that the methanol extract of P. niruri showed good 
in vivo and in vitro antiplasmodial activity against three 
strains of Plasmodium. The low level biological activity 
observed with the aqueous and ethanol extracts show that 
the bioactive components are not sufficiently present in 
these polar solvents unlike the highly non polar chloroform 
portion (F1). The observed difference may be attributed 
to the nature of the solvent. Similar observation has been 
reported by different investigators[28-30]. These observations 
indicate that the antiplasmodial components in ME are 
highly non-polar compounds, mainly resident in F1. This 
was also evident from its activity in established infection, 
which can be attributed to the localization of antiplasmodial 
active compounds in this fraction, relative to the crude 
extract. However, ME may be considered to possess better 
prophylactic antiplasmodial activity compared to its 
chloroform fraction F1, or pyrimethamine.
  It has been suggested that, membranolytic effect by 
substances on erythrocytes could not be precluded in 
predicting mechanisms of parasiticidal activity. This may 
not be involved in the antiplasmodial effects of ME and F1, 
as it did not cause disruption of erythrocytic membranes. 
Their effects may not however be unrelated to the 
antioxidant effect of P. niruri alcoholic extract as suggested 
by Harish and Shivanandappa[17] in a separate report. The 
results of phytochemical screening of F1 indicate a positive 
correlation between the antiplasmodial activity of F1 and the 
localization of terpenoid substances, which have been shown 
to confer some plants with antiplasmodial properties[31-37]. 
Some terpenoids previously isolated from the plant include 
limonene, p-cymene and lupeol[38] and these compounds 
may account for its antiplasmodial activity. These secondary 
metabolites have been implicated in endoperoxidation, 
leading to their parasiticidal effects on Plasmodium[25,39]. 
  The results of this study show that the chloroform fraction of 
P. niruri methanol extract possesses significant antimalarial 
activity in vivo and HPLC served as a useful analytical 
tool for its identification. Further work to isolate, purify 
and structurally elucidate the antiplasmodial compound(s) 
resident in this fraction is on going in our laboratories and 
will form a separate report.  
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